Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.

International journal of biological macromolecules - 1 Feb 2026

Fang Qixiang, You Chengyu, Xiao Xi, Yang Weiguang, Ma Longtu, Li Qingchao, Tao Yan, Dong Zhilong

Abstract excerpt

Cisplatin resistance remains a major challenge in bladder cancer. Although the tumor suppressor ASPP2 is a critical co-factor for TP53-mediated apoptosis, its role in metabolic reprogramming and cisplatin response remains unclear. This study aimed to delineate the mechanism by which ASPP2 regulates cisplatin sensitivity through metabolic reprogramming. We first assessed the clinical significance of ASPP2 using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis Regulatory Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Drug Resistance, Neoplasm

Share to Mevalonic Acid

Share to Tumor Suppressor Protein p53

Share to Ubiquitination

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 41581813
DOI: 10.1016/j.ijbiomac.2026.150490

Genes

WWP2
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.PMID 41581813Read ↗

DARS2 Promotes Bladder Cancer Progression by Enhancing PINK1-Mediated MitophagySemantic proximity Read ↗

UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress ControlSemantic proximity Read ↗

The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.Semantic proximity Read ↗

Oncoprotein CIP2A controls PKM2 dimer-tetramer transition through phosphorylation of serine 287 in non-small cell lung cancerSemantic proximity Read ↗

Doctors revise Declaration of HelsinkiSemantic proximity Read ↗

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerSemantic proximity Read ↗

Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCTSemantic proximity Read ↗

NPEPPS is a novel and druggable driver of platinum resistanceSemantic proximity Read ↗

Pyruvate kinase M2 interacts with DNA damage-binding protein 2 and reduces cell survival upon UV irradiation.Semantic proximity Read ↗

UBASH3B-mediated MRPL12 Y60 dephosphorylation inhibits LUAD development by driving mitochondrial metabolism reprogrammingSemantic proximity Read ↗

Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53.Semantic proximity Read ↗

Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.